'Del 5q' diaporamas de présentation

Quoi de nouveau dans les SMD ?

1.21k views • 92 slides

MDS: Classification and Advances in Therapy

MDS: Classification and Advances in Therapy. BTG2013. S. Varma PGIMER, Chandigarh India. MDS. Highly heterogeneous group of disorders Variable natural history Variable mortality rate Variable response to therapy Commonest cause of death Progressive bone marrow failure

677 views • 46 slides

Current Options and New Developments for Treating Myelodysplastic Syndromes

Current Options and New Developments for Treating Myelodysplastic Syndromes. Oct 19, 2019. Myelodysplastic Syndromes (MDS). Clonal disorders of the bone marrow characterized by: Low blood counts Ineffective production of blood cells Abnormal red cells, neutrophils and platelets

448 views • 44 slides

Lenalidomide Efficacy

Lenalidomide Efficacy. Alan List, MD Professor of Medicine and Oncology Chief, Division of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute University of South Florida College of Medicine. Lenalidomide Del 5q MDS Studies. MDS-001 (N = 43 MDS)

442 views • 24 slides

Sekeres MA et al. Proc ASH 2010 ; Abstract 332.

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). Sekeres MA et al. Proc ASH 2010 ; Abstract 332. Background.

82 views • 8 slides